BACE1 and Alzheimer disease: The BACE-1 inhibitor drugs but not the non-BACE-1 anti-AD drugs de-acidified endolysosomes, decreased endolysosome Fe2+ levels, increased cytosolic Fe2+ and ROS levels, increased mitochondrial Fe2+ and ROS levels, and caused mitochondrial membrane depolarization.